Clinical trials: Systemic Autoimmune Disease
Lupus Nephritis
Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children
The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.
- Trial name
- NCT07675291
- Testing
- rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide
- Volunteers
- 112 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Systemic Lupus Erthematosus, Systemic Vasculitis
Rare AutoImmune SElf-management Programme Development
The rare autoimmune rheumatic diseases (RAIRDs) are life-long multi-system diseases that are life or organ threatening. RAIRDs can impair quality of life similar to chronic diseases such as heart failure.
- Conditions
- Systemic Lupus Erthematosus, Systemic Vasculitis, Inflammatory Myositis, Systemic Sclerosis (SSc)
- Trial name
- RAISE (NCT06642870)
- Testing
- Non-interventional study
- Where
- United Kingdom
- Volunteers
- 360 people
- Sponsor
- University of the West of England
Lupus Erythematosus, Systemic
Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
The purpose of this study is to evaluate whether a short interactive video game device is associated with performance on standard measures of attention and problem solving in patients with systemic lupus erythematosus(SLE).
- Trial name
- NCT03746197
- Testing
- Project EVO Multi- Treatment
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Jewish Health
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus
The purpose of this study is to assess the safety and tolerability of JNJ-56022473 following multiple subcutaneous (SC) study agent administrations in subjects with Systemic Lupus Erythematosus (SLE) and to determine whether…
- Trial name
- NCT02920424
- Testing
- JNJ-56022473
- Where
- 3 sites in Germany
- Sponsor
- Janssen Research & Development, LLC
Lupus Nephritis, ANCA-associated Vasculitis
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
This study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval) design for dose escalation, with four predetermined…
- Conditions
- Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy - PLA2R Induced, IgG4-Related Diseases
- Trial name
- NCT06285279
- Testing
- FKC289
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Nanjing University School of Medicine
Systemic Lupus Erythematosus
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT04895696
- Testing
- Afimetoran
- Where
- 147 sites in United States, Argentina and 17 more
- Volunteers
- 248 people
- Sponsor
- Beeline Medicines Corporation
Systemic Lupus Erythematosus
Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
Systemic lupus erythematosus, also known as lupus or SLE, is a chronic, multisystem, autoimmune disease in which the body's internal system of defense attacks its own normal tissues.
- Trial name
- NCT00230035
- Testing
- Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT)
- Where
- 5 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Erythematosus, Systemic
Synergetic B-cell Immunomodulation in SLE - 2nd Study.
In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment…
- Trial name
- SynBioSe-2 (NCT03747159)
- Testing
- Belimumab Injection
- Where
- 4 sites in Netherlands
- Volunteers
- 71 people
- Sponsor
- Leiden University Medical Center
Healthy, Lupus Nephritis
Functional MRI in Lupus Nephritis
The primary objectives of the study are as follows: To develop and optimize a renal functional magnetic resonance imaging (MRI) protocol consisting of Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Blood-Oxygen…
- Trial name
- NCT01731054
- Where
- 4 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biogen
Inflammatory Rheumatism, Polymyalgia Rheumatica
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy.
- Conditions
- Inflammatory Rheumatism, Polymyalgia Rheumatica, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies
- Trial name
- PRODIGIOUS (NCT04664465)
- Where
- 12 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Lupus Nephritis
High Quality Evidence of Chinese Lupus Nephritis (HELP)
The investigators are registering LN patients at recruited hospitals and developing a LN database in China. Patients will be follow-up every year, and both baseline and follow-up information will be entered into the registration…
- Trial name
- NCT03001973
- Testing
- No Intervention
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sun Yat-sen University
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST (NCT05531565)
- Testing
- Litifilimab
- Where
- 315 sites in United States, Argentina and 28 more
- Volunteers
- 450 people
- Sponsor
- Biogen
Lupus Erythematosus, Systemic
Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus
In addition to the different pharmacological therapies available for the treatment of Systemic Lupus Erythematosus (SLE) as well as for its numerous associated complications (cutaneous, articular, hematological, neuropsychiatric…
- Trial name
- EFINUTRILES (NCT05261529)
- Testing
- Extra Virgin Olive Oil (EVOO), Physical Exercise Program
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Universidad de Granada
Systemic Lupus Erythematosus
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and…
- Trial name
- NCT00430677
- Testing
- Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
- Where
- 84 sites in United States, Argentina and 16 more
- Volunteers
- 423 people
- Sponsor
- Bristol-Myers Squibb
Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE)
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in…
- Conditions
- Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
- Trial name
- NCT07729826
- Testing
- C-CAR168
- Volunteers
- 50 people
- Sponsor
- AbelZeta Inc.
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).
- Trial name
- VOCAL (NCT05288855)
- Testing
- Voclosporin
- Where
- 6 sites in United States, Colombia and 3 more
- Volunteers
- 9 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Systemic Lupus Erythematosus
Lupus Arthritis: Muscoloskeletal Ultrasound as Clinical Outcome of Peripheral Blood and Synovial Deep Phenotyping
Musculoskeletal involvement, defined as arthritis/arthralgia, is the most common manifestation of patients with systemic lupus erythematosus (SLE).
- Trial name
- LUMAPS (NCT07102238)
- Testing
- muscoloskeletal ultrasound and synovial biopsy
- Where
- Italy
- Volunteers
- 269 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lupus Erythematosus, Systemic
A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab in Chinese participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard-of-care treatments.
- Trial name
- NCT04060888
- Testing
- Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 milligram (mg)
- Sponsor
- Janssen Research & Development, LLC
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal.
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Trial name
- NCT06339177
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis, Pemphigus Vulgaris
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris…
- Conditions
- Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
- Trial name
- IRIS-RD-01 (NCT06581562)
- Testing
- AB-101, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IRIS Research and Development, LLC